Every once in a while a discovery in the clinic exceeds researchers’ expectations. This is what happened in early February 2022 when Vicore, received early data from a Phase 2 study of our candidate product, C21, for idiopathic pulmonary fibrosis (IPF).
Article published in MedNous (Vol 16, No 3, March 2022)
Science